Antibodies against low-Density lipoprotein receptor-Related protein 4 induce myasthenia gravis

Journal of Clinical Investigation

Volumn 123, Issue 12, 2013, Pages 5190-5202

  Shen, Chengyong ^a   Lu, Yisheng ^a   Zhang, Bin ^a   Figueiredo, Dwight ^a   Bean, Jonathan ^a   Jung, Jiung ^a   Wu, Haitao ^a   Barik, Arnab ^a   Yin, Dong Min ^a   Xiong, Wen Cheng ^a,b   Mei, Lin ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGRIN; CHOLINERGIC RECEPTOR; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 4; MUSK PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURFACE; CONTROLLED STUDY; ELECTRON MICROSCOPY; FEMALE; MICROSCOPY; MOUSE; MUSCLE ACTION POTENTIAL; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL;

ANIMALS; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; HEK293 CELLS; HUMANS; LDL-RECEPTOR RELATED PROTEINS; MICE; MICE, INBRED A; MYASTHENIA GRAVIS; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; NEUROMUSCULAR JUNCTION; PROTEIN STRUCTURE, TERTIARY; RABBITS; RATS; RECEPTORS, LDL;

EID: 84890113189     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI66039     Document Type: Article

References (80)

1. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol. 2002;2(10):797-804.
2. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10:46.
3. Phillips LH 2nd. The epidemiology of myasthenia gravis. Ann N Y Acad Sci. 2003;998:407-412.
4. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry. 1985; 48(12):1246-1252.
5. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976; 26(11):1054-1059.
6. Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science. 1973; 180(4088):871-872.
7. Kao I, Drachman DB. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science. 1977;196(4289):527-529.
8. Bevan S, Heinemann S, Lennon VA, Lindstrom J. Reduced muscle acetylcholine sensitivity in rats immunised with acetylcholine receptor. Nature. 1976; 260(5550):438-439.
9. Lambert EH, Lindstrom JM, Lennon VA. End-plate potentials in experimental autoimmune myasthenia gravis in rats. Ann N Y Acad Sci. 1976;274:300-318.
10. Toyka KV, et al. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med. 1977;296(3):125-131.
11. Green DP, Miledi R, Vincent A. Neuromuscular transmission after immunization against acetylcholine receptors. Proc R Soc Lond B Biol Sci. 1975; 189(1094):57-68.
12. Engel AG, Tsujihata M, Lindstrom JM, Lennon VA. The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study. Ann N Y Acad Sci. 1976;274:60-79.
13. Lennon VA, Lindstrom JM, Seybold ME. Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs. J Exp Med. 1975;141(6):1365-1375.
14. Lennon VA, Lambert EH. Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature. 1980;285(5762):238-240.
15. Richman DP, Gomez CM, Berman PW, Burres SA, Fitch FW, Arnason BG. Monoclonal anti-acetylcholine receptor antibodies can cause experimental myasthenia. Nature. 1980;286(5774):738-739.
16. Aharonov A, Tarrab-Hazdai R, Abramsky O, Fuchs S. Immunological relationship between acetylcholine receptor and thymus: a possible significance in myasthenia gravis. Proc Natl Acad Sci U S A. 1975;72(4):1456-1459.
17. Engel AG, Arahata K. The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci. 1987;505:326-332.
18. Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc. 1977;52(5):267-280.
19. McMahan UJ. The agrin hypothesis. Cold Spring Harb Symp Quant Biol. 1990;55:407-418.
20. Kim N, et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell. 2008;135(2):334-342.
21. Zhang B, Luo S, Wang Q, Suzuki T, Xiong WC, Mei L. LRP4 serves as a coreceptor of agrin. Neuron. 2008; 60(2):285-297.
22. Wu H, Xiong WC, Mei L. To build a synapse: signaling pathways in neuromuscular junction assembly. Development. 2010;137(7):1017-1033.
23. Misgeld T, Kummer TT, Lichtman JW, Sanes Jr. Agrin promotes synaptic differentiation by counteracting an inhibitory effect of neurotransmitter. Proc Natl Acad Sci U S A. 2005;102(31):11088-11093.
24. Weatherbee SD, Anderson KV, Niswander LA. LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction. Development. 2006;133(24):4993-5000.
25. Zong Y, et al. Structural basis of agrin-LRP4-MuSK signaling. Genes Dev. 2012;26(3):247-258.
26. DeChiara TM, et al. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell. 1996;85(4):501-512.
27. Glass DJ, et al. Agrin acts via a MuSK receptor complex. Cell. 1996;85(4):513-523.
28. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365-368.
29. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003; 60(12):1978-1980.
30. McConville J, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004;55(4):580-584.
31. Shigemoto K, et al. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest. 2006;116(4):1016-1024.
32. Shigemoto K, et al. Myasthenia gravis experimentally induced with muscle-specific kinase. Ann N Y Acad Sci. 2008;1132:93-98.
33. Jha S, et al. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol. 2006;175(1-2):107-117.
34. Xu K, Jha S, Hoch W, Dryer SE. Delayed synapsing muscles are more severely affected in an experimental model of MuSK-induced myasthenia gravis. Neuroscience. 2006;143(3):655-659.
35. Punga AR, Lin S, Oliveri F, Meinen S, Rügg MA. Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice. Exp Neurol. 2011;230(2):207-217.
36. Mori S, et al. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Pathol. 2012;180(2):798-810.
37. Cole RN, Reddel SW, Gervásio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol. 2008; 63(6):782-789.
38. Cole RN, Ghazanfari N, Ngo ST, Gervásio OL, Reddel SW, Phillips WD. Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice. J Physiol. 2010; 588(pt 17):3217-3229.
39. ter Beek WP, et al. The effect of plasma from muscle- specific tyrosine kinase myasthenia patientson regenerating endplates. Am J Pathol. 2009; 175(4):1536-1544.
40. Klooster R, et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain. 2012; 135(pt 4):1081-1101.
41. Richman DP, et al. Acute severe animal model of antimuscle- specific kinase myasthenia: combined postsynaptic and presynaptic changes. Arch Neurol. 2012; 69(4):453-460.
42. Lu Y, Tian QB, Endo S, Suzuki T. A role for LRP4 in neuronal cell viability is related to apoE-binding. Brain Res. 2007;1177:19-28.
43. Johnson EB, Hammer RE, Herz J. Abnormal development of the apical ectodermal ridge and polysyndactyly in Megf7-deficient mice. Hum Mol Genet. 2005; 14(22):3523-3538.
44. Yamaguchi YL, Tanaka SS, Kasa M, Yasuda K, Tam PP, Matsui Y. Expression of low density lipoprotein receptor-related protein 4 (Lrp4) gene in the mouse germ cells. Gene Expr Patterns. 2006;6(6):607-612.
45. Tian QB, et al. Interaction of LDL receptor-related protein 4 (LRP4) with postsynaptic scaffold proteins via its C-terminal PDZ domain-binding motif, and its regulation by Ca/calmodulin-dependent protein kinase II. Eur J Neurosci. 2006;23(11):2864-2876.
46. Zong Y, et al. Structural basis of agrin-LRP4-MuSK signaling. Genes Dev. 2012;26(3):247-258.
47. Pevzner A, et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol. 2012;259(3):427-435.
48. Zhang B, et al. Autoantibodies to lipoproteinrelated protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol. 2012; 69(4):445-451.
49. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptorrelated protein 4 in myasthenia gravis. Ann Neurol. 2011;69(2):418-422.
50. Marx A, et al. Expression of neurofilaments and of a titin epitope in thymic epithelial tumors. Implications for the pathogenesis of myasthenia gravis. Am J Pathol. 1996;148(6):1839-1850.
51. Baggi F, et al. Anti-titin and antiryanodine receptor antibodies in myasthenia gravis patients with thymoma. Ann N Y Acad Sci. 1998;841:538-541.
52. Yamamoto AM, et al. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol. 2001; 58(6):885-890.
53. Giraud M, et al. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on antititin antibodies. Neurology. 2001;57(9):1555- 1560.
54. Nakayashiki N, Oshima M, Deitiker PR, Ashizawa T, Atassi MZ. Suppression of experimental myasthenia gravis by monoclonal antibodies against MHC peptide region involved in presentation of a pathogenic T-cell epitope. J Neuroimmunol. 2000; 105(2):131-144.
55. Roses AD, Olanow CW, McAdams MW, Lane RJ. No direct correlation between serum antiacetylcholine receptor antibody levels and clinical state of individual patients with myasthenia gravis. Neurology. 1981;31(2):220-224.
56. Pachner AR, Kantor FS. The relation of clinical disease to antibody titre, proliferative response and neurophysiology in murine experimental autoimmune myasthenia gravis. Clin Exp Immunol. 1983; 51(3):543-550.
57. Wu H, et al. Distinct roles of muscle and motoneuron LRP4 in neuromuscular junction formation. Neuron. 2012;75(1):94-107.
58. Tzartos SJ, Sophianos D, Zimmerman K, Starzinski- Powitz A. Antigenic modulation of human myotube acetylcholine receptor by myasthenic sera. Serum titer determines receptor internalization rate. J Immunol. 1986;136(9):3231- 3238.
59. Burden SJ, Yumoto N, Zhang W. The role of MuSK in synapse formation and neuromuscular disease. Cold Spring Harb Perspect Biol. 2013;5(5):a009167.
60. Ahn Y, Sims C, Logue JM, Weatherbee SD, Krumlauf R. Lrp4 and Wise interplay controls the formation and patterning of mammary and other skin appendage placodes by modulating Wnt signaling. Development. 2013;140(3):583-593.
61. McCann CM, Nguyen QT, Santo Neto H, Lichtman JW. Rapid synapse elimination after postsynaptic protein synthesis inhibition in vivo. J Neurosci. 2007; 27(22):6064-6067.
62. Kong XC, Barzaghi P, Ruegg MA. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference. EMBO Rep. 2004;5(2):183-188.
63. Hesser BA, Henschel O, Witzemann V. Synapse disassembly and formation of new synapses in postnatal muscle upon conditional inactivation of MuSK. Mol Cell Neurosci. 2006;31(3):470-480.
64. Klaus GG, Pepys MB, Kitajima K, Askonas BA. Activation of mouse complement by different classes of mouse antibody. Immunology. 1979; 38(4):687-695.
65. Neuberger MS, Rajewsky K. Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol. 1981;11(12):1012-1016.
66. Zhang G, et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain. 2004;127(pt 5):1085-1100.
67. Grodzki AC, Berenstein E. Antibody purification: ammonium sulfate fractionation or gel filtration. Methods Mol Biol. 2010;588:15-26.
68. Toyka KV, Brachman DB, Pestronk A, Kao I. Myasthenia gravis: passive transfer from man to mouse. Science. 1975;190(4212):397-399.
69. Hopf C, Hoch W. Dimerization of the musclespecific kinase induces tyrosine phosphorylation of acetylcholine receptors and their aggregation on the surface of myotubes. J Biol Chem. 1998; 273(11):6467-6473.
70. Zhang W, Coldefy AS, Hubbard SR, Burden SJ. Agrin binds to the N-terminal region of Lrp4 protein and stimulates association between Lrp4 and the first immunoglobulin-like domain in muscle-specific kinase (MuSK). J Biol Chem. 2011; 286(47):40624-40630.
71. Culican SM, Nelson CC, Lichtman JW. Axon withdrawal during synapse elimination at the neuromuscular junction is accompanied by disassembly of the postsynaptic specialization and withdrawal of Schwann cell processes. J Neurosci. 1998; 18(13):4953-4965.
72. Viegas S, et al. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects. Exp Neurol. 2012;234(2):506-512.
73. Karner CM, et al. Lrp4 regulates initiation of ureteric budding and is crucial for kidney formation - a mouse model for Cenani-Lenz syndrome. PLoS One. 2010;5(4):e10418.
74. Vandiedonck C, Giraud M, Garchon HJ. Genetics of autoimmune myasthenia gravis: the multifaceted contribution of the HLA complex. J Autoimmun. 2005; 25(suppl):6-11.
75. Niks EH, et al. Strong association of MuSK antibodypositive myasthenia gravis and HLA-DR14-DQ5. Neurology. 2006;66(11):1772-1774.
76. Buss RR, et al. Neuromuscular development in the absence of programmed cell death: phenotypic alteration of motoneurons and muscle. J Neurosci. 2006; 26(52):13413-13427.
77. Zhang B, Liang C, Bates R, Yin Y, Xiong WC, Mei L. Wnt proteins regulate acetylcholine receptor clustering in muscle cells. Mol Brain. 2012;5:7.
78. Luo S, et al. HSP90β regulates rapsyn turnover and subsequent AChR cluster formation and maintenance. Neuron. 2008;60(1):97-110.
79. Wu H, et al. β-Catenin gain of function in muscles impairs neuromuscular junction formation. Development. 2012;139(13):2392-2404.
80. Yang XL, Huang YZ, Xiong WC, Mei L. Neuregulin- induced expression of the acetylcholine receptor requires endocytosis of ErbB receptors. Mol Cell Neurosci. 2005;28(2):335-346.